Pretargeting redux: a bispecific antibody re-ignites radioimmunotherapy
Pretargeted
radioimmunotherapy (PRIT) combines antibody-mediated immunotherapy with
targeted delivery of radioisotopes. It is a multi-step process, first the
administration of a monoclonal antibody, followed by a clearing agent to remove
any unbound antibody. Then, a radiolabeled element is injected for antibody
binding and specific elimination of the targeted cancer cells.
Radioimmunotherapy has the potential to improve cancer treatment by increasing
specific tumor cell eradication and reducing toxicity. Radioimmunotherapy has
already been successful for leukemia and lymphoma treatments but evaluation in
the context of multiple myeloma (MM) has been very limited.
In a recent study
published in the journal Blood, the groups of Drs. Damian Green and Oliver
Press assessed radioimmunotherapy applied to MM by targeting CD38, a protein
whose expression is increased, stable and uniform in MM cells. CD38 has already
successfully been targeted with monoclonal antibody-mediated immunotherapy. However, relapses remain inevitable with the current
approaches.
In the study, a
newly designed bispecific antibody binding both to the CD38 antigen on one
extremity and to a radiolabeled isotope on the other extremity was
characterized. Two versions of the bispecific antibody were evaluated side by
side.
To read more please visit: https://www.fredhutch.org/en/news/spotlight/2018/01/crd_green_blood.html
Source: Fred Hutchlnson Cancer Research Center